Within three months of Akeso sharing the data, BioNTech paid $800 million to buy its PD-L1xVEGF bispecific partner Biotheus and Merck handed LaNova Medicines $588 million to enter the race. The ...

A benchmarking toolkit for comparing Kruskal's and Prim's minimum spanning tree algorithms across various graph configurations, with visualization tools and performance analysis reports. PCGEx is a ...